Your session is about to expire
← Back to Search
Leukocyte Tracking PET/MRI for Multiple Sclerosis
Study Summary
This trial will use PET/MRI to track white blood cells in people with conditions associated with brain inflammation. The hope is that by understanding neuroinflammation better, patients can be better diagnosed and treated in the future.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You cannot have gadolinium-based contrast agents for medical reasons.I do not have an autoimmune disease, except for MS.I have a blood or clotting disorder.I have been diagnosed with Chronic Fatigue Syndrome.You are a person who is healthy and without any medical conditions.I am between 18 and 65 years old.I have a long-term infection like HIV or hepatitis C.I haven't had a serious infection needing treatment in the last month.I have been diagnosed with cancer, including leukemia.You are pregnant when you take the Zirconium-89 Oxinate-4-labeled leukocytes.1. You are between 18 and 65 years old.
2. You are either a healthy volunteer or have been diagnosed with Multiple Sclerosis (MS), or meet specific medical criteria for fibromyalgia or Chronic Fatigue Syndrome.You cannot have an MRI for medical reasons.You have been diagnosed with fibromyalgia based on specific guidelines from the American College of Rheumatology.I have been diagnosed with Multiple Sclerosis.I am healthy or have been diagnosed with MS, fibromyalgia, or Chronic Fatigue Syndrome.
- Group 1: Multiple Sclerosis
- Group 2: Fibromyalgia
- Group 3: Healthy Controls
- Group 4: Chronic Fatigue Syndrome
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an ongoing call for volunteers to participate in this research?
"Affirmative. Per the information hosted on clinicaltrials.gov, this research project is actively searching for participants after having been first posted October 5th 2021 and lastly updated January 3rd 2022. The trial requires 120 individuals from a singular site to partake in it."
Is participation in the research open to octogenarians?
"For this clinical trial, only people within the age bracket of 18 to 65 are suitable candidates. For those under 18 and over 65, 83 studies and 696 studies respectively have been conducted."
Could you give me an overview of the current research surrounding [Zr-89]Oxine-labeled leukocytes PET/MRI?
"Currently, one [Zr-89]Oxine-labeled leukocytes PET/MRI clinical trial is underway and it has not yet reached Phase 3. This study is primarily based in Birmingham, Alabama but there are additional sites where the treatment can be accessed."
Has the [Zr-89]Oxine-labeled leukocytes PET/MRI been sanctioned by the FDA?
"The safety rating of [Zr-89]Oxine-labeled leukocytes PET/MRI was assessed at a 1, as this is an early phase trial with limited evidence demonstrating both efficacy and security."
Who is eligible to participate in this research initiative?
"Eligible patients must have fibromyalgia, be of legal age and under 65 years old. A total of 120 individuals are being recruited for the trial."
What is the enrollment rate for this experimental research project?
"Indeed, clinicaltrials.gov has indicated that this research project is still recruiting participants. The trial was published on October 5th 2021 and was last updated in January 3rd 2022; it requires 120 volunteers across one site to take part."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
What state do they live in?
What site did they apply to?
How many prior treatments have patients received?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger